2,887 reports of this reaction
7.0% of all RANIBIZUMAB reports
#2 most reported adverse reaction
VISUAL ACUITY REDUCED is the #2 most commonly reported adverse reaction for RANIBIZUMAB, manufactured by Genentech, Inc.. There are 2,887 FDA adverse event reports linking RANIBIZUMAB to VISUAL ACUITY REDUCED. This represents approximately 7.0% of all 41,498 adverse event reports for this drug.
Patients taking RANIBIZUMAB who experience visual acuity reduced should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
VISUAL ACUITY REDUCED is moderately reported among RANIBIZUMAB users, representing a notable but not dominant share of adverse events.
In addition to visual acuity reduced, the following adverse reactions have been reported for RANIBIZUMAB:
The following drugs have also been linked to visual acuity reduced in FDA adverse event reports:
VISUAL ACUITY REDUCED has been reported as an adverse event in 2,887 FDA reports for RANIBIZUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
VISUAL ACUITY REDUCED accounts for approximately 7.0% of all adverse event reports for RANIBIZUMAB, making it one of the most commonly reported side effect.
If you experience visual acuity reduced while taking RANIBIZUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.